All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 7th September, study results were published in Blood assessing the use of pomalidomide, bortezomib and dexamethasone (PVD) with relapsed Multiple Myeloma (MM) patients who are refractory to lenalidomide. Jonas Paludo from the Division of Hematology at the Mayo Clinic in Rochester, and colleagues, determined the maximum tolerated dose (MTD) and the efficacy and safety of PVD in phase I and II trials.
The study was prospective, non-randomized, multicenter, open-label and investigator-initiated. The phase I study determined the MTD of PVD and the efficacy and safety were evaluated in the phase II study. Phase II study endpoints included: Partial Response (PR), Objective Response Rate (ORR), Very Good Partial Response (VGPR) and Complete Response (CR). Secondary endpoints included: Overall Survival (OS), Progression-Free Survival (PFS), Duration of Response (DOR) and toxicity.
The results of this study showed good efficacy for the use of PVD in RRMM patients who are refractory to lenalidomide treatment. Safety profiles were shown to be acceptable, and dose reductions of bortezomib limited the major AE of neuropathy. Thus PVD is a convenient and well-tolerated regimen for use as a second line therapy for patients previously treated with lenalidomide. Given that the lower dose of 1 mg of bortezomib was only tested in 3 patients in the phase I portion of the trial, little conclusion can be drawn and it would be interesting to see if smaller dose reductions can retain efficacy whilst limiting resulting AEs.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox